Why the study?
Does monoclonal antibody VIS410 improve outcomes in adults with uncomplicated influenza A infection?
Does monoclonal antibody VIS410 improve outcomes in adults with uncomplicated influenza A infection?
Answers are grounded in this paper and cite their sources.
Supports further development of VIS410 for influenza A; extends randomized evidence for monoclonal antibodies targeting viral hemagglutinin.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hershberger et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: